Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR2303 in healthy adults
NCT07199270Phase 1Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GR2303 in inflammatory bowel disease (IBD) (8 arms), sponsored by Zhixiang Jintai. Primary endpoint: Adverse events at 16 weeks. Started Sep 2025; status: recruiting.
02
Drugs
GR2303
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07199270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199270.